Roles of Hippo-TAZ signaling pathway in breast cancer and breast cancer stem cells

doi:10.3760/cma.j.issn.1673-422X.2016.10.014

Abstract

Abstract: Hippo signaling pathway plays an important role in the regulation of organ growth, tissue regeneration, tumor occurrence and development. Transcriptional coactivator with PDZbinding motif (TAZ) is the downstream transcription factor of Hippo signaling, participates in the regulation of the entire signaling pathway. In recent years, many studies have found that overexpression of TAZ has a close relationship with the occurrence, development and prognosis of breast cancer. Discussing the relationship of HippoTAZ with breast cancer and breast cancer stem cells may provide a new way for breast cancer diagnosis and treatment.

Key words: Breast neoplasms, Neoplastic stem cells, Hippo signaling, Transcriptional coactivator with PDZbinding motif

Yan Bing, Lu Ying, Zhang Chunying, Li Qing, Mao Jun, Li Lianhong. Roles of Hippo-TAZ signaling pathway in breast cancer and breast cancer stem cells[J]. Journal of International Oncology, 2016, 43(10): 779-782.

References

［1］ Harvey KF, Zhang X, Thomas DM. The hippo pathway and human cancer［J］. Nat Rev Cancer, 2013, 13(4): 246-257. DOI: 10.1038/nrc3458. ［2］ Pan D. The hippo signaling pathway in development and cancer［J］. Dev Cell, 2010, 19(4): 491-505. DOI: 10.1016/j.devcel.2010.09.011. ［3］ Xiao H, Jiang N, Zhou B, et al. TAZ regulates cell proliferation and epithelialmesenchymal transition of human hepatocellular carcinoma［J］. Cancer Sci, 2015, 106(2): 151-159. DOI: 10.1111/cas.12587. ［4］ Xie D, Cui J, Xia T, et al. Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression［J］. Oncotarget, 2015, 6(34): 35949-35963. DOI: 10.18632/oncotarget.5772. ［5］ RomeroPérez L, GarciaSanz P, Mota A, et al. A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer［J］. Mod Pathol, 2015, 28(11): 1492-1503. DOI: 10.1038/modpathol.2015.102. ［6］ Cordenonsi M, Zanconato F, Azzolin L, et al. The hippo transducer TAZ confers cancer stem cellrelated traits on breast cancer cells［J］. Cell, 2011, 147(4): 759-772. DOI: 10.1016/j.cell.2011.09.048. ［7］ Azzolin L, Zanconato F, Bresolin S, et al. Role of TAZ as mediator of Wnt signaling［J］. Cell, 2012, 151(7): 1443-1456. DOI: 10.1016/j.cell.2012.11.027. ［8］ Lai D, Ho KC, Hao Y, et al. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF［J］. Cancer Res, 2011, 71(7): 2728-2738. DOI: 10.1158/00085472.CAN102711. ［9］ Zhao D, Zhi X, Zhou Z, et al. TAZ antagonizes the WWP1mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis［J］. Carcinogenesis, 2012, 33(1): 59-67. DOI: 10.1093/carcin/bgr242. ［10］ Chan SW, Lim CJ, Chen L, et al. The Hippo pathway in biological control and cancer development［J］. J Cell Physiol, 2011, 226(4): 928-939. DOI: 10.1002/jcp.22435. ［11］ Diepenbruck M, Waldmeier L, Ivanek R, et al. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelialmesenchymal transition［J］. J Cell Sci, 2014, 127(Pt 7): 1523-1536. DOI: 10.1242/jcs.139865. ［12］ Varelas X, SamavarchiTehrani P, Narimatsu M, et al. The crumbs complex couples cell density sensing to hippodependent control of the TGFβSMAD pathway［J］. Dev Cell, 2010, 19(6): 831-844. DOI: 10.1016/j.devcel.2010.11.012. ［13］ Wang Y, Zhou BP. Epithelialmesenchymal transition in breast cancer progression and metastasis［J］. Chin J Cancer, 2011, 30(9): 603-611. DOI: 10.5732/cjc.011.10226. ［14］ Huang W, Lv X, Liu C, et al. The Nterminal phosphodegron targets TAZ/WWTR1 protein for SCFβTrCPdependent degradation in response to phosphatidylinositol 3kinase inhibition［J］. J Biol Chem, 2012, 287(31): 26245-26253. DOI: 10.1074/jbc.M112.382036. ［15］ Bartucci M, Dattilo R, Moriconi C, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells［J］. Oncogene, 2015, 34(6): 681-690. DOI: 10.1038/onc.2014.5. ［16］ Mi W, Lin Q, Childress C, et al. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration［J］. Oncogene, 2015, 34(24): 3095-3106. DOI: 10.1038/onc.2014.251. ［17］ Piccolo S, Cordenonsi M, Dupont S. Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis［J］. Clin Cancer Res, 2013, 19(18): 4925-4930. DOI: 10.1158/10780432.CCR123172. ［18］ Zanconato F, Forcato M, Battilana G, et al. Genomewide association between YAP/TAZ/TEAD and AP1 at enhancers drives oncogenic growth［J］. Nat Cell Biol, 2015, 17(9): 1218-1227. DOI: 10.1038/ncb3216. ［19］ Yang N, Morrison CD, Liu P, et al. TAZ induces growth factorindependent proliferation through activation of EGFR ligand amphiregulin［J］. Cell Cycle, 2012, 11(15): 2922-2930. DOI: 10.4161/cc.21386. ［20］ Ehmer U, Sage J. Control of proliferation and cancer growth by the Hippo signaling pathway［J］. Mol Cancer Res, 2016， 14（2）：127-140. DOI: 10.1158/15417786.MCR150305. ［21］ Hiemer SE, Szymaniak AD, Varelas X. The transcriptional regulators TAZ and YAP direct transforming growth factor βinduced tumorigenic phenotypes in breast cancer cells［J］. J Biol Chem, 2014, 289(19): 13461-13474. DOI: 10.1074/jbc.M113.529115. ［22］ Keller PJ, Arendt LM, Skibinski A, et al. Defining the cellular precursors to human breast cancer［J］. Proc Natl Acad Sci USA, 2012, 109(8): 2772-2777. DOI: 10.1073/pnas.1017626108. ［23］ Lu Y, Ma W, Mao J, et al. Salinomycin exerts anticancer effects on human breast carcinoma MCF7 cancer stem cells via modulation of Hedgehog signaling［J］. Chem Biol Interact, 2015, 228(228): 100-107. DOI: 10.1016/j.cbi.2014.12.002. ［24］ Lai D, VisserGrieve S, Yang X. Tumour suppressor genes in chemotherapeutic drug response［J］. Biosci Rep, 2012, 32(4): 361-374. DOI: 10.1042/BSR20110125. ［25］ Chang C, Goel HL, Gao H, et al. A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells［J］. Genes Dev, 2015, 29(1): 1-6. DOI: 10.1101/gad.253682.114. ［26］ Luo M, Brooks M, Wicha MS. Epithelialmesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance［J］. Curr Pharm Des, 2015, 21(10): 1301-1310. ［27］ Sorrentino G, Ruggeri N, Specchia V, et al. Metabolic control of YAP and TAZ by the mevalonate pathway［J］. Nat Cell Biol, 2014, 16(4): 357-366. DOI: 10.1038/ncb2936. ［28］ Fernández BG, Gaspar P, BrásPereira C, et al. ActinCapping protein and the hippo pathway regulate factin and tissue growth in drosophila［J］. Development, 2011, 138(11): 2337-2346. DOI: 10.1242/dev.063545. ［29］ Thomasy SM, Morgan JT, Wood JA, et al. Substratum stiffness and latrunculin B modulate the gene expression of the mechanotransducers YAP and TAZ in human trabecular meshwork cells［J］. Exp Eye Res, 2013, 113: 66-73. DOI: 10.1016/j.exer.2013.05.014.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng. Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors [J]. Journal of International Oncology, 2023, 50(11): 650-654.